001052289 001__ 1052289
001052289 005__ 20260122203309.0
001052289 0247_ $$2doi$$a10.1002/alz70856_099181
001052289 0247_ $$2ISSN$$a1552-5260
001052289 0247_ $$2ISSN$$a1552-5279
001052289 0247_ $$2datacite_doi$$a10.34734/FZJ-2026-00906
001052289 037__ $$aFZJ-2026-00906
001052289 082__ $$a610
001052289 1001_ $$0P:(DE-Juel1)194451$$aAhmadi, Reihaneh$$b0$$eCorresponding author
001052289 245__ $$aThe Association between Sleep Disturbances, Imaging Biomarkers and Cognitive Decline along the Trajectory of Alzheimer's Disease
001052289 260__ $$aHoboken, NJ$$bWiley$$c2025
001052289 3367_ $$2DRIVER$$aarticle
001052289 3367_ $$2DataCite$$aOutput Types/Journal article
001052289 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1769086972_20074
001052289 3367_ $$2BibTeX$$aARTICLE
001052289 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001052289 3367_ $$00$$2EndNote$$aJournal Article
001052289 520__ $$aBackgroundAlzheimer's Disease (AD) is a prevalent and debilitating neurodegenerative condition that significantly impacts global health. Increasing evidence indicates that sleep disturbances, including insomnia and Sleep-Disordered Breathing (SDB), may act as modifiable risk factors for AD. Despite extensive research into AD biomarkers, the complex interactions between sleep disturbances, neuroimaging biomarkers, and cognitive decline across the AD continuum remain insufficiently explored. This study aimed to investigate the relationships between self-reported sleep disturbances, specifically insomnia and SDB, and imaging biomarkers associated with AD.MethodData from 1510 participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI) were analyzed. Imaging biomarkers, including tau and amyloid Positron Emission Tomography (PET) and structural Magnetic Resonance Imaging (MRI), were examined alongside self-reported sleep disturbances and cognitive performance scores from the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog). Statistical analyses explored the effects of sleep disturbances on imaging biomarkers and cognitive outcomes while controlling for demographic and clinical factors.ResultComparative analyses revealed that overall sleep disturbances and their interaction with AD diagnosis significantly impact tau deposition in key AD-sensitive brain regions, including the amygdala, fusiform, inferior temporal and parietal cortices, and posterior cingulate cortex (corrected p-value < 0.05). These regions are particularly vulnerable during the middle stages of AD. Distinct patterns emerged for insomnia and SDB, with SDB showing a more pronounced and earlier influence on both AD pathology and cognitive decline compared to insomnia. The findings suggest that SDB may be a more critical factor in accelerating AD progression, emphasizing the need for early intervention.ConclusionThis study demonstrates that sleep disturbances significantly contribute to tau burden and cognitive decline in AD, with SDB exhibiting an earlier and more pronounced impact than insomnia. These findings highlight the importance of targeting sleep disturbances to mitigate tau-related pathology, protect cognitive function, and slow disease progression. Early diagnosis and targeted interventions for sleep disturbances could provide significant therapeutic benefits in managing AD and improving patient outcomes.
001052289 536__ $$0G:(DE-HGF)POF4-5252$$a5252 - Brain Dysfunction and Plasticity (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001052289 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001052289 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz70856_099181$$gVol. 21, no. S2, p. e099181$$nS2$$pe099181$$tAlzheimer's and dementia$$v21$$x1552-5260$$y2025
001052289 8564_ $$uhttps://juser.fz-juelich.de/record/1052289/files/Alzheimer%20s%20Dementia%20-%202025%20-%20Ahmadi%20-%20The%20Association%20between%20Sleep%20Disturbances%20Imaging%20Biomarkers%20and%20Cognitive.pdf$$yOpenAccess
001052289 909CO $$ooai:juser.fz-juelich.de:1052289$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
001052289 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)194451$$aForschungszentrum Jülich$$b0$$kFZJ
001052289 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5252$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001052289 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
001052289 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
001052289 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
001052289 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
001052289 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-06$$wger
001052289 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
001052289 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
001052289 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
001052289 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
001052289 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
001052289 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-06
001052289 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
001052289 920__ $$lyes
001052289 9201_ $$0I:(DE-Juel1)INM-7-20090406$$kINM-7$$lGehirn & Verhalten$$x0
001052289 9801_ $$aFullTexts
001052289 980__ $$ajournal
001052289 980__ $$aVDB
001052289 980__ $$aUNRESTRICTED
001052289 980__ $$aI:(DE-Juel1)INM-7-20090406